These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4587066)

  • 1. Diphenylhydantoin effectiveness in the treatment of chronic schizophrenics. A double-blind controlled study with a placebo.
    Simopoulos AM; Pinto A; Uhlenhuth EH; McGee JJ; DeRosa ER
    Arch Gen Psychiatry; 1974 Jan; 30(1):106-11. PubMed ID: 4587066
    [No Abstract]   [Full Text] [Related]  

  • 2. A controlled study of the effects of diphenylhydantoin on anxiety, irritability, and anger in neurotic outpatients.
    Stephens JH; Shaffer JW
    Psychopharmacologia; 1970; 17(2):169-81. PubMed ID: 4392689
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of diphenylhydantoin on anxiety and hostility in institutionalized prisoners.
    Gottschalk LA; Covi L; Uliana R; Bates DE
    Compr Psychiatry; 1973; 14(6):503-11. PubMed ID: 4587507
    [No Abstract]   [Full Text] [Related]  

  • 4. Responses of chronic schizophrenic females to a combination of diphenylhydantoin and neuroleptics: a double-blind study.
    Pinto A; Simopoulos AM; Uhlenhuth EH; DeRosa ER
    Compr Psychiatry; 1975; 16(6):529-36. PubMed ID: 1104252
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.
    Tuason VB
    J Clin Psychiatry; 1986 Mar; 47(3):126-9. PubMed ID: 3512535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study.
    Silver H; Nassar A
    Biol Psychiatry; 1992 Apr; 31(7):698-704. PubMed ID: 1599987
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study.
    Silver H; Blacker M; Weller MP; Lerer B
    Biol Psychiatry; 1991 Sep; 30(5):523-5. PubMed ID: 1932400
    [No Abstract]   [Full Text] [Related]  

  • 8. Low dose bromocriptine: a study of acute effects in chronic mediated schizophrenics.
    Cutler NR; Jeste DV; Kaufmann CA; Karoum F; Schran HF; Wyatt RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):277-83. PubMed ID: 6146164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
    Saletu B; Saletu M; Itil T; Marasa J
    Biol Psychiatry; 1971; 3(4):299-307. PubMed ID: 5163816
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose naloxone administration in chronic schizophrenia.
    Cohen MR; Pickar D; Cohen RM
    Biol Psychiatry; 1985 May; 20(5):573-5. PubMed ID: 3886025
    [No Abstract]   [Full Text] [Related]  

  • 12. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.
    Grebb JA; Shelton RC; Taylor EH; Bigelow LB
    Biol Psychiatry; 1986 Jun; 21(7):691-4. PubMed ID: 3518822
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of schizophrenia with a vasopressin analogue.
    Iager AC; Kirch DG; Bigelow LB; Karson CN
    Am J Psychiatry; 1986 Mar; 143(3):375-7. PubMed ID: 3513631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between plasma concentrations of chlorpromazine and clinical response.
    Rivera-Calimlim L; Gift T; Nasrallah HA; Wyatt RJ; Lasagna L
    Commun Psychopharmacol; 1978; 2(3):215-22. PubMed ID: 699536
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment-resistant schizophrenia: controlled study of moderate- and high-dose thiothixene.
    Huang CC; Gerhardstein RP; Kim DY; Hollister L
    Int Clin Psychopharmacol; 1987 Jan; 2(1):69-75. PubMed ID: 3312398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia.
    Chengappa KN; Goldstein JM; Greenwood M; John V; Levine J
    Clin Ther; 2003 Feb; 25(2):530-41. PubMed ID: 12749512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyrotropin-releasing hormone in schizophrenia.
    Davis KL; Hossister LE; Berger PA
    Am J Psychiatry; 1975 Sep; 132(9):951-3. PubMed ID: 808141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient use of a double-blind medication trial: a clinical example.
    Diamond RJ
    J Clin Psychiatry; 1983 Aug; 44(8):304-5. PubMed ID: 6874651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of quetiapine on aggression and hostility in patients with schizophrenia.
    Arango C; Bernardo M
    Hum Psychopharmacol; 2005 Jun; 20(4):237-41. PubMed ID: 15830402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.